Application and clinical progress of pyrotinib in breast cancer
10.3760/cma.j.cn115355-20230813-00047
- VernacularTitle:吡咯替尼在乳腺癌中的应用及临床进展
- Author:
Maiyue HE
1
;
Jiaxuan LIU
;
Qiao LI
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肿瘤内科，北京 100021
- Keywords:
Breast neoplasms;
Receptor, epidermal growth factor;
Human epidermal growth factor receptor 2;
Tyrosine kinase inhibitors;
Pyrotinib
- From:
Cancer Research and Clinic
2024;36(3):229-232
- CountryChina
- Language:Chinese
-
Abstract:
Pyrotinib is a new irreversible epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) dual tyrosine kinase inhibitor, and it has shown excellent clinical efficacy in treatment of HER2-positive breast cancer patients. The combination of pyrotinib and capecitabine in the treatment of advanced breast cancer has been recognized at home and abroad. Further exploration of whether there are other antitumor agents that work well in combination with pyrotinib, and whether pyrotinib can enhance clinical benefit in patients with early-stage or middle-stage breast cancer, could develop additional potential of pyrotinib. This article reviews the progress related to pyrotinib in recent years.
